Session » Systemic Lupus Erythematosus – Clinical Poster II: Biomarkers and Outcomes

Date: Monday, October 22, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1691

Application of the Doris Algorithm for the Definition of Disease Remission and Its Relation with Damage Accrual over a 2-Year Period in a Cohort of Italian Patients with Systemic Lupus Erythematosus Classified According to Clinical Disease Patterns

9:00AM-11:00AM: Abstract Number: 1713

Attainment of Low Disease Activity and Remission in SLE Patients Who Started with High Disease Activity in the Atacicept Phase IIb Address II Study and Its Long-Term Extension

9:00AM-11:00AM: Abstract Number: 1699

Autoantibodies to M-Phase Phosphoprotein I (MPP-1: KIF20B) in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1688

Changes in Heart Rate Variability Reflect Clinical Improvement and Flare in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1704

Clinical SLE Disease Activity Index Score of Zero May be a More Pragmatic Outcome Measure in SLE Studies

9:00AM-11:00AM: Abstract Number: 1667

Confirmatory Factor Analysis of the Patient-Reported Perceived Deficits Questionnaire in Systemic Lupus Erythematosus: Cautions for Use of Subscales

9:00AM-11:00AM: Abstract Number: 1668

Construction and Validation of a Frailty Index As a Novel Health Measure in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1682

Correlation between SLE Specific and Generic Health Related Quality of Life Surveys, and Their Association with Patient Global Rating of Change and Lupus Low Disease Activity State: A Longitudinal Study

9:00AM-11:00AM: Abstract Number: 1706

Development of an Online Lupus Self-Management Program Based on the Transtheoretical Model of Change

9:00AM-11:00AM: Abstract Number: 1695

Differences between Early and Adult-Onset Systemic Lupus Erythematosus in Cohort of Argentinian Patients

9:00AM-11:00AM: Abstract Number: 1670

Disease Course Patterns in Systemic Lupus Erythematosus: Impact on Long-Term Outcomes

9:00AM-11:00AM: Abstract Number: 1677

Evaluation of Erythrocyte Sedimentation Rate As a Marker of Disease Activity in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1689

Explaining the Discrepancy between Physician and Patient-Reported Measures of Disease Activity in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1664

Fatigue Measurements in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1703

Fragmented Qrs in Patients with Systemic Lupus Erythematosus: Relation to the Disease Activity: A Cross-Sectional Study

9:00AM-11:00AM: Abstract Number: 1676

Health Related Quality of Life over Time in a Multi-Ethnic Cohort of Patients with Systemic Lupus Erythematosus and Correlation with Disease Activity and Organ Damage

9:00AM-11:00AM: Abstract Number: 1678

How Consistently Do Publications Define SLE? a Systematic Review

9:00AM-11:00AM: Abstract Number: 1669

iC3b/C3 Ratios More Strongly Correlate with SLE Disease Activity in African-Americans Compared to Whites

9:00AM-11:00AM: Abstract Number: 1685

IL2 Decrease Is Associated to ANTI-DNA Positivity in Systemic LUPUS Erythematous Patients

9:00AM-11:00AM: Abstract Number: 1696

Impact of Hurricane Maria on a Cohort of Systemic Lupus Erythematosus Patients from Puerto Rico

9:00AM-11:00AM: Abstract Number: 1690

Increased Sensitivity Οf Τhe New (2017) Αnd Τhe 2012 SLICC As Compared Τo Τhe Acr 1997 Classification Criteria Ιn Early Systemic Lupus Erythematosus (SLE): The 2017 Αnd 2012 Criteria May Classify Non-Overlapping Subgroups Οf Patients

9:00AM-11:00AM: Abstract Number: 1693

Innate, Adaptive, and TNF-Superfamily Immune Pathways Inform a Lupus Disease Activity Immune Index That Characterizes Disease Activity in SLE

9:00AM-11:00AM: Abstract Number: 1671

Laboratory Investigation Results Influence Physician’s Global Assessment of Disease Activity in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1665

Longitudinal Stratification of Gene Expression Reveals Three SLE Groups of Disease Activity Progression

9:00AM-11:00AM: Abstract Number: 1675

Lupus Impact Tracker Responds to Changes in Low Disease Activity and Remission Outcomes in a Large Spanish Lupus Registry Cohort

9:00AM-11:00AM: Abstract Number: 1674

Lupus Impact Tracker Validation in a Large European Spanish Lupus Registry Cohort

9:00AM-11:00AM: Abstract Number: 1701

Lupus Low Disease Activity State: Predicting Organ Damage Accrual and Cardiovascular Risk in Patients with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1681

Performance of the Proposed American College of Rheumatology / European League Against Rheumatism 2017 Classification Criteria for SLE in Adult and Juvenile Systemic Lupus Erythematosus and Other Anti-Nuclear Antibody Related Rheumatic Diseases

9:00AM-11:00AM: Abstract Number: 1710

Polypharmacy in Older Adults with Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1672

Poor Sleep Quality Predicts Worsening SLE Disease Activity

9:00AM-11:00AM: Abstract Number: 1707

Prolactin and Dehydroepiandrosterone Sulfate in Women with Active Systemic Lupus Erythematosus of Recent Onset Versus Chronic Inactive Patients

9:00AM-11:00AM: Abstract Number: 1684

Prolonged Remission/Low Disease Activity State Is Associated with a Better Health-Related Quality

9:00AM-11:00AM: Abstract Number: 1697

Refractory Lupus Patients: How Frequent Do We See Them in the 21st Century?

9:00AM-11:00AM: Abstract Number: 1700

Remission and Low Disease Activity State Prevent Hospitalizations and Emergency Room Visits in Systemic Lupus Erythematosus Patients

9:00AM-11:00AM: Abstract Number: 1686

Rule-Based Algorithm Using Systemic Lupus International Collaborating Clinics (SLICC) Classification Criteria to Identify Patients with Systemic Lupus Erythematosus (SLE) from Electronic Health Record (EHR) Data

9:00AM-11:00AM: Abstract Number: 1680

Serum Calprotectin in Systemic Lupus Erythematosus: Is It a Good Activity Biomarker?

9:00AM-11:00AM: Abstract Number: 1708

Serum Complement Regulatory Proteins and Disease Activity of Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1687

Systemic Lupus Flares Based on BILAG and Sledai Rules Are Inconsistent, but May be Better Understood Using Visual Analogue Scales

9:00AM-11:00AM: Abstract Number: 1698

The Association between Periodontitis and the Disease Activity of Systemic Lupus Erythematosus: A Cross-Sectional Study

9:00AM-11:00AM: Abstract Number: 1694

The Lupus Severity Index Accurately Identifies Patients with Severe SLE in a Multi-Ethnic Cohort

9:00AM-11:00AM: Abstract Number: 1666

The Use of Patient-Reported Outcome Measures to Assess Clinical Features of Fibromyalgia in SLE

9:00AM-11:00AM: Abstract Number: 1705

Trajectory Analysis of Combined Disease Activity and Physical Component Summary Scale in an Inception Cohort of Adults with Systemic Lupus Erythematosus: Latent Classes Inform Different Patterns

9:00AM-11:00AM: Abstract Number: 1679

Usefulness of Cardiac Screening in Patients with Systemic Lupus Erythematosus and Anti-Ro Positive Antibodies

9:00AM-11:00AM: Abstract Number: 1692

Using ICD-10-CM Codes to Identify Patients with Systemic Lupus Erythematosus in the Electronic Health Record

9:00AM-11:00AM: Abstract Number: 1702

Utility of the Avise Connective Tissue Disease Test in Predicting Lupus Diagnosis and Progression of Disease

9:00AM-11:00AM: Abstract Number: 1711

Utility of the Lupus Low Disease Activity State (LLDAS) in Discriminating Responders in the BLISS-52 and BLISS-76 Phase 3 Trials of Intravenous Belimumab in Systemic Lupus Erythematosus

9:00AM-11:00AM: Abstract Number: 1709

Utilization of Complementary and Integrative Medicine Among Lupus Patients:a Patient Centered Analysis of Perceived Effectiveness and Preference

9:00AM-11:00AM: Abstract Number: 1673

Validation and Evaluation of the Spanish Version of the Systemic LUPUS Activity Questionnaire in an Argentine Population

9:00AM-11:00AM: Abstract Number: 1712

Validation of Proposed EULAR/Acr SLE Classification Criteria Versus SLICC SLE Classification Criteria

9:00AM-11:00AM: Abstract Number: 1683

Variation in HEp-2 Antinuclear Antibody (ANA) Titer Is Strongly Associated with the ANA Kit Manufacturer

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].